Moderna (MRNA) is running up today after the company said it will have data supporting its coronavirus vaccine for children under the age of 6 to the Food & Drug Administration next month for review. That’s good news for us, as we were assigned shares last week.
However, given that the company is scheduled to report earnings this week, I want to sell our shares on this rally to avoid earnings risk. I will recommend a put to sell after the announcement to reduce our net debit on the position.
If you are an Income Masters member, note that we continue to track the ongoing net debit we have in MRNA in that program as well.
Current Stock Price: $145.40
Cost Basis: $152.78
Action: Sell shares at market
Net Debit: $7.38